Zacks Investment Research upgraded shares of TherapeuticsMD Inc (NASDAQ:TXMD) from a sell rating to a hold rating in a research report sent to investors on Thursday morning.

According to Zacks, “TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida. “

TXMD has been the topic of a number of other research reports. Jefferies Group reissued a buy rating on shares of TherapeuticsMD in a report on Wednesday, June 8th. Noble Financial restated a buy rating and issued a $17.50 price target on shares of TherapeuticsMD in a research note on Monday, July 11th.

Shares of TherapeuticsMD (NASDAQ:TXMD) traded up 0.16% during mid-day trading on Thursday, hitting $6.27. The company’s stock had a trading volume of 239,891 shares. The company’s market cap is $1.23 billion. The stock has a 50-day moving average of $6.97 and a 200-day moving average of $7.64. TherapeuticsMD has a 12-month low of $5.18 and a 12-month high of $11.26.

TherapeuticsMD (NASDAQ:TXMD) last released its earnings results on Thursday, August 4th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.10) by $0.01. The firm earned $4.40 million during the quarter, compared to analyst estimates of $5.63 million. The company’s revenue for the quarter was down 8.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.16) earnings per share. On average, equities research analysts forecast that TherapeuticsMD will post ($0.43) EPS for the current year.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare product company. The Company’s segment is creating and commercializing products for women. It is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. Its drug candidates are created using its SYMBODA hormone technology, which enables the administration of hormones with high bioavailability alone or in combination.

5 Day Chart for NASDAQ:TXMD

Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with's FREE daily email newsletter.